


Urine-based Liquid Biopsy

Trovagene, Inc. (NASDAQ: TROV) is a molecular diagnostics company specializing in non-invasive cell-free diagnostics. Trovagene has developed a broad intellectual property portfolio of more than 60 issued patents, spanning cancer, infectious disease, organ transplant and prenatal diagnostics using this technology. The Company's current focus is the development of its technology for Precision Cancer MonitoringSM, using droplet digital PCR and next-generation sequencing techniques to identify and quantify circulating tumor DNA (ctDNA) mutations as a surrogate for tumor load and response to therapy. Use of these non-invasive tests can enable physicians to better monitor a patient's treatment response, and change treatment if medically necessary.

Circulating Tumor DNA (ctDNA)



Non-Invasive Cancer Monitoring

Our revolutionary precision cancer monitoring technology is setting out to change the way cancer is treated and monitored through simple, non-invasive sampling of cell-free nucleic acids instead of traditional invasive tissue biopsies.

Tracking Cell-Free DNA

Cells in the body die continuously; cancer cells die at an accelerated rate. DNA is released into the bloodstream, which is then broken down into smaller segments and filtered by the kidney. Small, stable DNA fragments collect in urine where Trovagene technology can isolate, identify and quantify mutations of interest.

Unique Diagnostic Technology

Our technology is enabling the development of non-invasive detection of disease through analysis of cell-free nucleic acid markers in urine. Tracking changes in the tumor's genomic expression and measuring the quantity of mutations present may provide actionable information to better guide treatment decisions.

Research

Scientists at Trovagene were the first to make the simple yet remarkable discovery that circulating cell-free nucleic acids cross the kidney barrier. The detection of cell-free nucleic acids have enabled new, non-invasive molecular diagnostics.

Enabling Benefits of Urine Collection

Large sample volume	Convenient, non-invasive
Larger sample of ctDNA	No refrigeration required
Cell-free DNA stable in urine	Lower cost
High frequency of collection possible	Samples can be shipped at room temperature

Financials

\$44M cash on hand on March 31, 2015

\$275M market cap on May 31, 2015

\$23.4M shares outstanding on March 31, 2015

Trovagene, Inc.
11055 Flintkote Avenue
Suite A
San Diego, CA 92121
USA

+1 858.952.7593
ir@trovagene.com



www.trovagene.com